Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CTSB | P07858 | 1/20 | 0.55 |
| ▸ | PPP3CB | P16298 | 1/20 | 0.55 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.40 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.40 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13997826 | 1.00 | CYP3A4 (0.60) | CYP3A4CTSBPPP3CBABCC1ABCC2 | |
| SCHEMBL8275350 | 1.00 | CYP3A4 (0.60) | CYP3A4CTSBPPP3CBABCC1ABCC2 | |
| SCHEMBL845223 | 1.00 | CYP3A4 (0.60) | CYP3A4CTSBPPP3CBABCC1ABCC2 | |
| SCHEMBL8351109 | 1.00 | CYP3A4 (0.60) | CYP3A4CTSBPPP3CBABCC1ABCC2 | |
| SCHEMBL14031119 | 0.96 | CYP3A4 (0.59) | CYP3A4CTSBPPP3CB | |
| SCHEMBL375308 | 0.96 | CTSB (0.56) | CYP3A4CTSBPPP3CBABCC1ABCC2 | |
| SCHEMBL7724759 | 0.94 | CYP3A4 (0.53) | CYP3A4CTSBPPP3CBABCC1ABCC2 | |
| SCHEMBL12161229 | 0.94 | CYP3A4 (0.53) | CYP3A4CTSBPPP3CBABCC1ABCC2 | |
| SCHEMBL14264362 | 0.94 | CYP3A4 (0.53) | CYP3A4CTSBPPP3CBABCC1ABCC2 | |
| SCHEMBL13707597 | 0.94 | CYP3A4 (0.53) | CYP3A4CTSBPPP3CBABCC1ABCC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1505945-B1 | SUBSTITUTED CYCLOALKYL P1' HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-11-05 | — | — | EP | disclosed |
| EP-1337550-B1 | HEPATITIS C TRIPEPTIDE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2006-05-24 | — | — | EP | disclosed |
| US-6878722-B2 | Substituted cycloalkyl P1′ hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-12 | — | — | US | disclosed |
| US-6872805-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-03-29 | — | — | US | disclosed |
| US-20040077551-A1 | Substituted cycloalkyl P1' hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-22 | — | — | US | disclosed |
| EP-1337550-A2 | HEPATITIS C TRIPEPTIDE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-08-27 | — | — | EP | disclosed |
| US-20020111313-A1 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2002-08-15 | — | — | US | disclosed |
| WO-2002060926-A2 | HEPATITIS C TRIPEPTIDE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020111313-A1 | Hepatitis C virus inhibitors | HAVCR2, ZC3HAV1, VIP | CYP3A4 3102/4885CTSB 188/4885PPP3CB 171/4885 |
| US-20040077551-A1 | Substituted cycloalkyl P1' hepatitis C virus inhibitors | HAVCR2, ANPEP, ENPEP | CYP3A4 2730/4885CTSB 203/4885PPP3CB 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.